BBHC
CLVS

Brown Brothers Harriman & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

Brown Brothers Harriman & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-63
Closed -$4K – 1191
2017
Q4 		$4K Buy
+63
New +$4.41K ﹤0.01% 914

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Brothers Harriman & Co's CLVS Position: Q1 2018 in Review

Brown Brothers Harriman & Co sold out of Clovis Oncology, Inc. (CLVS) in Q1 2018, closing a stake of 63 shares — an estimated $4K sold.

Brown Brothers Harriman & Co first reported a position in CLVS in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 229 funds tracked by Wall St. Rank hold CLVS as of Q1 2018.

  • Brown Brothers Harriman & Co reported no remaining Clovis Oncology, Inc. position as of Q1 2018 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 63 Clovis Oncology, Inc. shares in Q1 2018, an estimated $4K.
  • Brown Brothers Harriman & Co first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 1 quarter.
  • Brown Brothers Harriman & Co's Clovis Oncology, Inc. position peaked at $4K in Q4 2017.
  • 229 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2018.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2018, filed 14 May 2018.